bullous disease

大疱性疾病
  • 文章类型: Case Reports
    天疱疮(PF)是天疱疮的表面形式。PF的治疗选择类似于寻常型天疱疮,包括糖皮质激素,免疫抑制剂和利妥昔单抗等。这些治疗方法可以有效改善病情,但也可能伴随着高风险的副作用。因此,为PF患者寻找安全有效的治疗方案至关重要。它不仅对拒绝糖皮质激素或免疫抑制剂治疗的患者有益/必要,也适用于不能使用糖皮质激素或免疫抑制剂治疗的患者。在这里,我们报道了1例PF患者接受apremilast治疗,但未使用全身性糖皮质激素或免疫抑制剂.一名54岁的妇女在躯干上出现瘙痒红斑和糜烂超过1个月。患者应用莫米他酮糠酸乳膏持续两周没有改善。既往有糖尿病及萎缩性胃炎病史。体格检查发现躯干上有散在的红斑和糜烂。未观察到粘膜受累。通过天疱疮病区指数和数字评定量表评估病情,基线评分分别为7分和8分。组织病理学检查显示棘皮松解和上皮内起泡。直接免疫荧光显示,网状细胞之间存在IgG和补体3沉积。根据酶联免疫吸附测定结果,Dsg1和Dsg3抗体水平分别为28.18和0.26kU/L。诊断为PF。该患者成功接受了apremilast治疗,没有全身性糖皮质激素或免疫抑制剂。患者继续每天一次使用apremilast30mg进行维持,在9个月的随访期间未观察到与apremilast相关的不良事件,例如胃肠道副作用。总之,不使用全身性糖皮质激素或免疫抑制剂的apremilast治疗可能为治疗轻度PF提供有效的替代方案,而没有明显的副作用。
    Pemphigus foliaceus (PF) is a superficial form of pemphigus. Treatment options for PF resemble pemphigus vulgaris, including glucocorticosteroids, immunosuppressive agents and rituximab et al. These treatment approaches can effectively improve the condition but may also be accompanied by high risks of side effects. Therefore, it is crucial to find a safe and effective treatment options for patients with PF. It will not only benefit/be necessary for patients who refuse glucocorticosteroids or immunosuppressive agents treatments, but also for patients who cannot be treated with glucocorticosteroids or immunosuppressive agents. Herein, we reported a case of PF that was treated with apremilast without systemic glucocorticosteroids or immunosuppressive agents. A 54-year-old woman presented with itchy erythema and erosions on the trunk for more than 1 month. The patient applied mometasonefuroate cream without improvement for a duration of two weeks. The past history of diabetes mellitus and atrophic gastritis was reported. Physical examination revealed scattered erythematous macules and erosions on the trunk. No mucosal involvement was observed. The condition was assessed by the pemphigus disease area index and numerical rating scale, with baseline scores of 7 and 8, respectively. Histopathological examination showed acantholysis and intraepithelial blister. Direct immunofluorescence revealed the presence of IgG and Complement 3 deposition between the acanthocytes with the reticular distribution. Based on enzyme-linked immunosorbent assay results, the levels of Dsg1 and Dsg3 antibodies were 28.18 and 0.26 kU/L respectively. The diagnosis of PF was made. This patient was successfully treated with apremilast without systemic glucocorticosteroids or immunosuppressive agents. The patient has continued with apremilast 30mg once daily for maintenance and no adverse events related to apremilast such as gastrointestinal side effects were observed during the 9-month follow-up period. In conclusion, apremilast therapy without systemic glucocorticosteroids nor immunosuppressive agents might provide an effective alternative to management of mild PF without obvious side effect.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Observational Study
    目的:寻常型天疱疮(PV)和大疱性类天疱疮(BP)是两种常见的大疱性疾病。先前的研究发现,BP的抗体可以在肠上皮中表达,并且BP与炎症性肠病密切相关。因此,肠道菌群也可能在大疱性疾病中发挥重要作用。然而,肠道菌群与大疱性疾病之间的具体关系尚不清楚。我们的研究旨在探讨肠道菌群在不同大疱性疾病发生发展中的潜在作用。
    方法:我们在北京协和医院进行了一项前瞻性观察性队列研究。招募未治疗的BP和PV患者,以及作为这些患者的配偶或照顾者的健康对照(HC)。收集粪便样本,然后进行16SrRNA基因测序。进行生物信息学分析以评估肠道微生物群的组成和功能。
    结果:共38HC,32BP,19例PV患者纳入本研究。与HC相比,BP,和PV表现出不同的肠道微生物群组成,尤其是BP。肠道菌群变化主要在拟杆菌门,Firmicutes,和变形杆菌。粪杆菌与埃希氏菌-志贺氏菌的比率(F/E比率)对于从PV识别BP具有相当大的预测值(AUC:0.705)。粪杆菌和肠杆菌的水平与抗BP180和抗桥粒蛋白3相关。微生物功能预测显示,BP患者肠道菌群易位相关途径的活性升高,表明在BP中潜在的致病作用。
    结论:我们的研究表明,肠道微生物群的组成在不同的大疱性疾病中是特定的,并且肠道微生物群的作用不同。肠道菌群可以帮助区分BP和PV,并可能在不同大疱性疾病的发病机制中起作用。
    OBJECTIVE: Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are two prevalent bullous diseases. Previous studies found that the antibodies of BP could be expressed in the intestinal epithelium and BP was tightly related to inflammatory bowel disease. Therefore, gut microbiota might also play an important role in bullous disease. However, the specific relationship between gut microbiota and bullous diseases remains unknown. Our study aimed to investigate the potential role of gut microbiota in the development and progression of different bullous diseases.
    METHODS: We conducted a prospective and observational cohort study at Peking Union Medical College Hospital. Untreated BP and PV patients were recruited, along with healthy controls (HC) who were spouses or caregivers of these patients. Fecal samples were collected, followed by 16S rRNA gene sequencing. Bioinformatics analyses were performed to assess the composition and function of gut microbiota.
    RESULTS: A total of 38 HC, 32 BP, and 19 PV patients were enrolled in this study. Compared to HC, BP, and PV exhibited a distinct gut microbiota composition, especially BP. The gut microbiota changes were mainly observed in the phylum Bacteroidetes, Firmicutes, and Proteobacteria. The ratio of Faecalibacterium to Escherichia-Shigella (F/E ratio) had a considerable predictive value (AUC: 0.705) for recognizing BP from PV. The levels of Faecalibacterium and Enterobacter were correlated to the anti-BP 180 and anti-desmoglein 3. Microbial functional prediction revealed elevated activity in pathways related to gut microbiota translocation significantly increased in BP patients, indicating a potential pathogenetic role in BP.
    CONCLUSIONS: Our study suggests that the composition of gut microbiota is specific in different bullous diseases and the role of gut microbiota differs. Gut microbiota could help distinguish BP and PV, and might play a role in the pathogenesis of different bullous diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号